Elritercept
Based on 1 Customer Validation
Elritercept (KER-050) is a modified activin type IIA receptor ligand trap. Elritercept binds to and neutralizes TGF-β superfamily ligands, including TGF-β, activins (activins), GDF8, GDF11 , and GDFs, blocking ActRIIa-mediated signaling, inhibiting SMAD2/3 signaling, and rebalancing signaling. Elritercept can be used in research on myelodysplastic syndromes, myelofibrosis, MDS/MF-associated anemia, and acute myeloid leukemia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 97.868%
- CAS 番号: 2727114-26-1
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Species Reactivity
Human
|
TGF-β |
activins |
GDF8 |
GDF11 |
ActRIIa |
Smad2 |
Smad3 |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C1498-GFP mouse AML cells
-
Concentration:400 ng/mL (alone and in combination with ActA 100 ng/mL)
-
Incubation Time:overnight pre-incubation; 4 h (migration assessment)
-
Result:Migratory ability of the AML cells was significantly reduced.
AML cells pre-incubated with an ActA-containing combination showed significantly reduced migration compared with ActA-pre-incubated cells.
ActA-induced migration of AML cells was inhibited.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 9 weeks old)[6]
-
Dosage:10 mg/kg
-
Administration:intraperitoneal (IP) injection; twice weekly; 3 weeks
-
Result:Increased RBCs (+21%), hemoglobin (+16%), hematocrit (+16%), and reticulocytes (+21%) compared to vehicle control.
Increased BM osteoblast (+81%) and BMSC (+23%) populations compared to vehicle control.
Did not change CFU-F numbers compared to vehicle control.
Increased CFU-ALP (+52%) compared to vehicle control.
Increased CFU-Ob (+36%) compared to vehicle control.
Did not change CFU-ADP numbers compared to vehicle control.
Increased osteoblast marker gene expression, osterix (Sp7) and osteocalcin (Ocn), with no changes in adipocyte marker gene expression compared to vehicle control.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
FPIA_[PROTEIN]2-FC
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Activin A Protein, Human (Biotinylated, HEK293, Avi, HY-P703994) can bind Elritercept. The EC50 for this effect is 9.269 ng/mL.
化学情報
-
CAS 番号 2727114-26-1
-
性状 Liquid
-
Color Colorless to light yellow
-
別名
KER-050
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Elritercept 関連分類
HY-P990720 関連分類
Powered by Bioz